Michael D. Axelson

1 ta ish

Bristol-Myers Squibb (United States)

1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

   Michael J. Overman, Ray McDermott, Joseph L. Leach +13

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.241933